Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$915.00
-9.00 (-0.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-5.5B · quality 64.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$70.7B
P/E
5657.1x
↑EV/EBITDA
51.8x
↑ROE
0.1%
↓Gross Margin
40.6%
↓Debt/Equity
0.94
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+28.2%
FCF CAGR
—
FCF margin
-15.7%
FCF / Net income
-444.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $35.27B · net income $12.5M · FCF $-5.55B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $35.27B | $35.27B | $26.05B | $26.03B | $16.73B |
| Net Income | $12.5M | $12.5M | $-2.34B | $-3.75B | $-790.2M |
| EBITDA | $1.67B | $1.67B | $147.6M | $-1.02B | $1.74B |
| EPS | 0.16 | 0.16 | -31.00 | -60.00 | -13.00 |
| Gross Margin | 40.6% | 40.6% | 39.6% | 33.5% | 29.2% |
| Operating Margin | 0.8% | 0.8% | -6.8% | -12.4% | -19.5% |
| Net Margin | 0.0% | 0.0% | -9.0% | -14.4% | -4.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.94 | 0.94 | 0.74 | 1.45 | 0.86 |
| Current Ratio | 0.95 | 0.95 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.55B | $-5.55B | $-6.39B | $-4.34B | $-7.71B |
| Returns | |||||
| ROE | 0.1% | 0.1% | -11.9% | -30.5% | -4.9% |
| Valuation | |||||
| P/E | 5657.12 | 5657.12 | — | — | — |
| EV/EBITDA | 51.78 | 51.78 | 586.85 | — | 31.22 |
| P/B | 3.55 | 3.55 | 3.88 | 6.11 | 2.80 |
| Growth & Yield | |||||
| Revenue Growth | 35.4% | 35.4% | 0.1% | 55.6% | — |
| EPS Growth | 100.5% | 100.5% | 48.3% | -361.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
694.7%
EPS terminal req.
$81.19
Spread vs growth
-594.2%
5Y implied EPS CAGR
260.3%
EPS terminal req.
$98.24
Spread vs growth
-159.8%
10Y implied EPS CAGR
99.1%
EPS terminal req.
$158.22
Spread vs growth
1.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-31.00 → 0.16
Residual
-28.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.